반응식
[NH2:1][C@@H:2]1[CH2:6][CH2:5][N:4]([C:7]2[N:15]=[C:14]3[C:10]([N:11]=[CH:12][N:13]3[C@@H:16]3[CH2:20][C@H:19]([NH:21][C:22](=[O:25])[CH2:23][CH3:24])[C@@H:18]([OH:26])[C@H:17]3[OH:27])=[C:9]([NH:28][CH2:29][CH:30]([C:38]3[CH:43]=[CH:42][C:41]([OH:44])=[CH:40][CH:39]=3)[C:31]3[CH:36]=[CH:35][C:34]([OH:37])=[CH:33][CH:32]=3)[N:8]=2)[CH2:3]1.[ClH:45].[C:46]([Cl:54])(=[O:53])[C:47]1[CH:52]=[CH:51][N:50]=[CH:49][CH:48]=1>C1COCC1.CN1C(=O)CCC1>[ClH:54].[ClH:45].[OH:44][C:41]1[CH:42]=[CH:43][C:38]([CH:30]([C:31]2[CH:36]=[CH:35][C:34]([OH:37])=[CH:33][CH:32]=2)[CH2:29][NH:28][C:9]2[N:8]=[C:7]([N:4]3[CH2:5][CH2:6][C@@H:2]([NH:1][C:46](=[O:53])[C:47]4[CH:52]=[CH:51][N:50]=[CH:49][CH:48]=4)[CH2:3]3)[N:15]=[C:14]3[C:10]=2[N:11]=[CH:12][N:13]3[C@@H:16]2[CH2:20][C@H:19]([NH:21][C:22](=[O:25])[CH2:23][CH3:24])[C@@H:18]([OH:26])[C@H:17]2[OH:27])=[CH:39][CH:40]=1참가 물질
6
반응물 2
생성물 2
시약·촉매·용매 2
실험 절차
A mixture comprising N-((1S,2R,3S,4R)-4-{2-((R)-3-amino-pyrrolidin-1-yl)-6-[2,2-bis-(4-hydroxy-phenyl)-ethylamino]-purin-9-yl}-2,3-dihydroxy-cyclopentyl)-propionamide (Example 22 step 4) (20 mg, 33 μmol) in THF (0.5 ml) and NMP (0.5 ml) is treated with TEA (13 mg, 0.13 mmol) followed by isonicotinoyl chloride hydrochloride (16 mg, 83 μmol). After stirring at room temperature for 2 hours, the solvent is removed in vacuo and purification by C-18 reverse phase column chromatography eluting with acetonitrile:water:HCl (0.1%) (gradient of 0 to 100% acetonitrile) yields the title compound. (MH+ 708.4)
후처리
- customthe solvent is removed in vacuo and purification by C-18 reverse phase column chromatography
- washeluting with acetonitrile
출처 및 근거
- ORD 기록
- ord-1a44f918f635453098f935faaafa6e0a
- 출처 데이터셋
- uspto-grants-2012_11
- 특허 번호
- US08318750B2
연결된 노트
불러오는 중…